CEO Executive AssistantPharma strategic review process CEO design is one of the highest-leverage governance investments a pharmaceutical executive makes. The annual strategic review – if designed and executed well – aligns your leadership team on direction, produces clear investment and priority decisions, and sets the agenda that your quarterly reviews execute against. Done poorly, it consumes four to six weeks of leadership team energy, produces a PowerPoint deck that is largely forgotten by February, and creates false confidence in a plan that has not actually been agreed upon by the people expected to execute it.
The CEOs who build effective strategic review processes have learned, often through experience with ineffective ones, what distinguishes a review that produces real decisions from one that produces an appearance of planning. The principles are not complicated. Their execution requires discipline.
The Purpose of an Annual Strategic Review
Start with clarity on purpose. The annual strategic review should accomplish four specific things:
External environment assessment: What has changed in the competitive landscape, the regulatory environment, the payer market, and the scientific domain that should change your strategic priorities or operating assumptions?
Portfolio and program decisions: Which pipeline programs are you advancing, de-prioritizing, or terminating for the coming year? What is the resource allocation across the portfolio and how has it shifted from the prior year?
Strategic priority setting: What are the two to four strategic priorities that will define organizational focus for the coming year? These are not operational objectives; they are the areas where strategic progress is essential and where leadership team attention will be concentrated.
Resource and capability decisions: What organizational capabilities need to be built or acquired in the coming year? What partnerships or BD transactions should you pursue? What workforce or operational changes does the strategy require?
If your strategic review is not producing specific, documented decisions on each of these dimensions, it is not doing its job.
Designing the Strategic Review Process
Start Eight Weeks Before the Review Meeting
The strategic review meeting itself is not where strategy is made. It is where leadership team decisions are made on work that has been done. The quality of the strategic review is largely determined by the quality of the preparatory work that precedes the meeting.
Eight weeks before the strategic review meeting, assign specific analytical owners for each major topic: your CSO and CMO for portfolio and pipeline analysis, your CCO and Head of Market Access for commercial and access environment assessment, your CFO for financial framework and resource scenarios, your CHRO for organizational capability assessment, and your Head of BD for external innovation and partnership opportunities.
Each analytical team produces a structured brief – not a full strategy presentation, but a focused analysis of the key strategic questions and their recommended answers. These briefs go to the CEO and leadership team two weeks before the strategic review meeting, as pre-read materials.
Structure the Meeting Around Decisions, Not Presentations
The most common strategic review design failure is organizing the meeting around sequential functional presentations. Each function presents its analysis, receives acknowledgment, and the meeting moves to the next function. At the end of two days, you have heard a lot but decided little.
Redesign the meeting structure around explicit decisions. The agenda should list the specific decisions the meeting needs to produce: “Pipeline prioritization: which programs are Tier 1 for 2026, and what are the resource implications?” “Commercial strategy: Do we expand the sales force or invest in omnichannel analytics capability, and what is the three-year model for each?” “Geographic expansion: Do we enter Japan and South Korea in the next 18 months or defer to 2028?”
Each agenda item ends with a documented decision or, if the data is insufficient, a documented next step to produce the data needed for the decision. The CEO’s role is to drive decisions at the meeting, not to let complex discussions end without resolution.
Use External Facilitation for the Meeting Itself
The strategic review meeting is one of the few occasions where external facilitation – a skilled facilitator who is not a member of the leadership team – can add significant value. The CEO, as a participant in strategic debates as well as the final decision-maker, is in a structural conflict between participating in the discussion and managing the process.
An external facilitator manages time, ensures all voices are heard, synthesizes areas of agreement, surfaces unresolved tensions explicitly, and keeps the meeting progressing toward decisions. The CEO’s attention is freed to focus on the substance of the discussion and to exercise the judgment that only the CEO can provide.
The CEO’s Specific Strategic Review Responsibilities
Setting the Strategic Frame Before the Meeting Begins
Two to three weeks before the strategic review meeting, the CEO should communicate a strategic frame to the leadership team: what questions are most important to resolve at this review, and what are your current hypotheses or intuitions about the answers? This is not direction-setting that forecloses the discussion; it is the CEO’s signal about where the most consequential decisions lie.
This communication can be as simple as a one-page CEO memo covering: what you believe the most important strategic question of the year is, where you have the most uncertainty and need the leadership team’s best thinking, and what you expect the strategic review to produce. Sharing your current thinking, including your uncertainties, models the intellectual honesty you want from the team.
Conducting Productive Bilateral Conversations Before the Meeting
The most consequential conversations in a strategic review often happen in the days and weeks before the meeting, when you have individual conversations with key leadership team members about the decisions facing the company. These one-on-one conversations surface individual perspectives and concerns that team dynamics in a group setting can suppress.
Budget one-hour conversations with your CMO, CSO, CCO, and CFO in the two weeks before the strategic review meeting. Use these conversations to understand each leader’s perspective on the key strategic questions, to surface any major points of disagreement that need structured discussion at the meeting, and to understand where each leader feels the current strategy is most at risk.
The CEO who goes into the strategic review meeting having already engaged each leadership team member individually can facilitate a much more productive group conversation, because they know where the actual points of divergence are and can address them directly.
The Strategic Review Meeting Facilitation Role
During the meeting, the CEO’s primary task is to guide the group toward the decisions that need to be made. This means actively summarizing areas of agreement, explicitly naming areas of disagreement, asking the clarifying questions that move discussions from talking points to genuine resolution, and making the CEO call when the leadership team has reached the limit of productive debate without convergence.
Not every decision will be made by consensus. Some of the most important strategic decisions – pipeline prioritization trade-offs, geographic expansion timing, make-versus-buy in manufacturing, significant resource reallocation – will have reasonable advocates on different sides. The CEO’s role is to hear those arguments, assess them, and make a call that the leadership team can then execute with full effort, even if individual members would have made a different choice.
Document decisions during the meeting, not afterward. Assign a strategic review scribe to produce real-time decision documentation, reviewed by the CEO at the end of each session. Decisions that are not documented at the time they are made tend to be reinterpreted or re-debated afterward.
Following the Strategic Review Through the Year
A strategic review that does not produce actions is a planning exercise without management value. Following the annual review:
Produce a strategy summary document: Not a 200-slide deck, but a five to ten page summary of the strategic priorities, the portfolio decisions, the resource allocations, and the major capability investments for the year. This document is shared with the full leadership team and, in appropriate form, with the board.
Establish quarterly strategy check-ins: Four times per year, dedicate 60 minutes of your leadership team meeting to strategy: Are we executing against the priorities we set? Have any major environmental changes required us to update our assumptions? Are there decisions that were deferred at the annual review that now need to be made?
Connect the strategy to resource processes: Your annual budget, your quarterly business reviews, and your pipeline reviews should all explicitly reference the strategic priorities from the annual review. Organizational decisions that are inconsistent with the stated strategic priorities should trigger a conversation about whether the strategy has changed or whether the decision is misaligned.
The pipeline review cadence is the most direct execution link from the strategic review: the pipeline priorities you set in the annual review define the investment framework that quarterly pipeline reviews manage against.
For board governance, the board reporting pharma function should include a strategic review summary at the board meeting following the annual review, and strategy progress should be a quarterly board agenda item. Boards that review strategic priorities only once a year have insufficient visibility into whether the organization is executing its stated direction.
Common Failures and How to Prevent Them
The strategy document that nobody reads: Strategy documents that are too long, too complex, or too abstract are not useful. If you cannot summarize the year’s strategic priorities on one page, the strategy is too complex to execute.
Consensus that is not actually consensus: Teams that appear to reach agreement in a meeting but where individual members leave with different interpretations of what was decided. Prevent this with explicit decision documentation and by checking alignment at the end of each agenda item: “Let me summarize what I heard us deciding, and I want to check that we are all in agreement.”
Annual strategy that does not survive the first major disruption: A strategy that is brittle under unexpected events (a competitor breakthrough, a regulatory setback, a pricing policy change) was not a real strategy – it was a best-case plan. Build explicit contingency thinking into the strategic review: “If our Phase III reads out negative, what does that do to our strategy? If the IRA negotiation is more aggressive than we projected, how do we adapt?”
Conclusion
Pharma strategic review process CEO design is the governance architecture that ensures your organization’s energy is directed toward the right priorities with consistent clarity throughout the year. The executives who build effective strategic reviews invest in the preparation that makes the meeting substantive, facilitate the meeting toward real decisions rather than structured presentations, and follow the review with the management discipline that converts decisions into organizational action. The annual strategic review is not a planning ritual. It is the primary mechanism by which a CEO coordinates the intelligence and energy of a complex organization toward a coherent direction.
Related Reading
For further context, explore Pharma CEO Time Management for Autoimmune Disease Strategy and Biomarker-Driven Trial Management: What Pharma CEOs Must Decide and When.